United States Patent 8,242,158: Scope, Claims, and U.S. Patent Landscape for Ready-to-Use Dexmedetomidine Parenteral Liquid in Sealed Glass
What does U.S. Drug Patent 8,242,158 claim, in scope terms?
U.S. Patent 8,242,158 claims a ready-to-use, parenteral liquid pharmaceutical composition whose defining combination is:
- Drug substance: dexmedetomidine or a pharmaceutically acceptable salt
- Concentration: about 4 μg/mL
- Container/packaging: a sealed glass container
- Optional formulation limitation: sodium chloride at 0.01 to 2.0 wt%, with a dependent claim specifying about 0.9 wt%
- Optional volume limitation: total volume selected from 20 mL, 50 mL, 100 mL
This is a narrow “formulation + concentration + container” composition claim set, with dependent claims dialing in salt/excipient concentration and pack size.
Claim-by-claim scope map
| Claim |
Core scope elements |
What narrows the invention |
| 1 |
Ready-to-use parenteral liquid; dexmedetomidine (salt allowed) at about 4 μg/mL; disposed within a sealed glass container |
Locks dose concentration and glass container in the composition itself |
| 2 |
Claim 1 + sodium chloride 0.01 to 2.0 wt% |
Adds a defined electrolyte range |
| 3 |
Claim 2 + sodium chloride about 0.9 wt% |
Fixes NaCl to a near-physiologic value (0.9%) |
| 4 |
Claim 1 + total volume 20 mL, 50 mL, or 100 mL |
Limits pack size of the ready-to-use unit |
Important practical consequence for design-around: the claims are drafted so that concentration (4 μg/mL) and sealed glass container are inseparable anchor features for claim 1. Variations in excipients or pack volumes only matter if claim 1 is avoided.
What is the legal and technical coverage of claim 1?
Structural elements (in claim 1)
Claim 1 requires all of the following:
- “Ready to use liquid pharmaceutical composition”
- The formulation is meant for direct administration (typical interpretation: no further dilution/reconstitution steps required before parenteral dosing).
- “Parenteral administration to a subject”
- Routes include injection/infusion by standard medical practice; the claim is not limited to IV vs IM etc. but “parenteral” requires non-oral administration.
- Dexmedetomidine (or pharmaceutically acceptable salt)
- Salt forms are explicitly included, so substitution among acceptable salts does not avoid the claim.
- Concentration “about 4 μg/mL”
- The concentration is a hard numerical anchor. “About” introduces some flexibility, but the center of gravity is 4 μg/mL.
- “Disposed within a sealed glass container”
- This ties the product to a specific container class and packaging state. It is not just “packaged in glass”; it is a sealed glass container and “disposed within” suggests the claim covers the product as presented in that container.
Scope boundaries for claim 1
Based on the text alone, claim 1 is not limited to:
- a specific buffer system (other than the concentration and presence/absence of NaCl via dependent claims)
- a specific pH
- stabilizer/surfactant amounts (not recited)
- a specific administration method (only “parenteral”)
So claim 1’s scope is broad on excipient design except where dependent claims impose sodium chloride and volume.
What claim 1 captures commercially
A product that is:
- dexmedetomidine (or salt)
- in a ready-to-use concentration centered on 4 μg/mL
- in a sealed glass vial/syringe-type container
- used for parenteral administration to patients
falls within the core.
How do dependent claims 2 and 3 expand or narrow?
Claim 2: sodium chloride range
Claim 2 adds NaCl at 0.01 to 2.0 wt% to the claim 1 formulation.
Coverage impact:
- If a competitor’s formulation has the same 4 μg/mL dexmedetomidine in sealed glass but uses no sodium chloride or uses outside 0.01–2.0 wt%, claim 2 does not apply.
- Claim 2 does not remove claim 1 coverage. If claim 1 is met, claim 1 may still apply regardless of NaCl level.
Claim 3: sodium chloride fixed to ~0.9 wt%
Claim 3 specifies about 0.9 wt% sodium chloride. That is a stricter subrange.
Coverage impact:
- If NaCl is between 0.01 and 2.0 wt% but not near 0.9 wt%, claim 3 may not apply while claim 2 can.
- If NaCl is outside 0.01–2.0 wt%, neither claim 2 nor 3 applies, but claim 1 still can.
How does claim 4 affect packaging/market design?
Claim 4 adds a total volume limitation: 20 mL, 50 mL, or 100 mL.
Coverage impact:
- A 4 μg/mL dexmedetomidine product in sealed glass that uses different volumes (e.g., 10 mL, 25 mL, 30 mL) may avoid claim 4 while still potentially falling under claim 1.
- Claim 4 is therefore a narrower protection layer on unit presentation.
What is the likely claim construction pressure point: “sealed glass container”?
The most litigated element in many formulation-packaging cases is the packaging feature because it can be altered without changing the drug concentration. Here, claim 1 requires:
A design-around strategy that changes container material (plastic, coated polymer, glass-with-open system, or non-sealed arrangement) can break the claim 1 element even if the formulation matches concentration.
However, the key issue is that claim 1 is written as a composition disposed within the container. If an accused product is presented as a sealed glass unit at sale and administration, it can still meet this element.
What does this imply for the U.S. patent landscape around dexmedetomidine ready-to-use liquids?
Without additional text of the patent record (title, assignee, prosecution history, and cited references), the landscape characterization must be limited to what is implied by the claim elements you provided:
1) Landscape segmentation by “anchor elements”
Most competitive U.S. filings in this area usually cluster around these variables:
- Concentration of dexmedetomidine (numerical)
- Ready-to-use vs concentrate (dilution requirement)
- Container type and closure (glass vs non-glass; sealed presentation)
- Excipient system (e.g., NaCl presence and level; buffers)
- Pack volume
U.S. Patent 8,242,158 is positioned at the intersection of:
- dexmedetomidine around 4 μg/mL
- ready-to-use parenteral
- sealed glass container
- NaCl optional range and fixed 0.9 wt% in dependents
- unit volumes 20/50/100 mL in dependent claim 4
2) Where infringement risk concentrates
Risk concentrates when a competitor product matches all elements of claim 1:
- dexmedetomidine at about 4 μg/mL
- ready-to-use for parenteral administration
- supplied in sealed glass
Then:
- if NaCl is in the dependent ranges, risk expands to claims 2/3
- if product is sold as 20/50/100 mL units, risk expands to claim 4
3) Where competitors are likely to aim design-arounds
Because claim 1’s anchor elements are concentration and sealed glass disposition, typical design-around directions are:
- Keep dexmedetomidine but change the container class (avoid “sealed glass”).
- Keep sealed glass but change the concentration (avoid “about 4 μg/mL” center).
- Keep both but change from ready-to-use to a form that requires dilution/reconstitution, avoiding “ready to use.”
- Change unit sizes to avoid claim 4’s discrete volume options (20/50/100 mL) while still managing claim 1 risk.
This is consistent with how narrow formulation claims are typically defeated: change one anchor element, then ensure the new presentation does not fall back under “about” or “disposed within.”
How broad is “about 4 μg/mL” in practice?
“About” introduces tolerance, but it does not eliminate the concentration constraint.
From a business perspective, treat “about 4 μg/mL” as:
- a centered target for match, not an open-ended interval
- a limitation that competitors will avoid by selecting a concentration that is not plausibly “about” 4 μg/mL under typical scientific and regulatory assay tolerance logic
Absent the patent specification and prosecution record, the exact numerical interpretation of “about” cannot be pinned to a specific bracket solely from the claim text you provided. The commercial reality is that any “close” concentration strategy should expect to be litigated against the intrinsic record.
What can be inferred about claim strategy and likely prosecution posture?
The claim format suggests:
- The invention is not merely the drug substance; it is a specific solution strength and presentation.
- Dependent claims add excipient and volume constraints, suggesting the inventor identified incremental patentable boundaries:
- NaCl range (claim 2) and specific near-physiologic level (claim 3)
- discrete volumes (claim 4)
This is a classic structure when applicants seek both:
- a broad independent claim on the anchor formulation
- fallback positions that tighten to more specific embodiments if the broad formulation is challenged.
Key Takeaways
- Claim 1 defines the core product: dexmedetomidine (or salt) at about 4 μg/mL in a ready-to-use parenteral liquid disposed within a sealed glass container.
- Claim 2 adds NaCl 0.01 to 2.0 wt%; Claim 3 fixes NaCl about 0.9 wt%.
- Claim 4 further limits unit volume to 20 mL, 50 mL, or 100 mL.
- In the U.S. landscape, infringement risk concentrates on matching claim 1’s anchor elements; dependent claims matter only if claim 1 is already met.
- The strongest design-around levers, conceptually, are container class (avoid “sealed glass”), concentration (avoid “about 4 μg/mL”), and ready-to-use presentation (avoid direct-use liquid if applicable).
FAQs
-
Does the patent cover dexmedetomidine salts?
Yes. Claim 1 includes dexmedetomidine or a pharmaceutically acceptable salt.
-
Is sodium chloride required to practice claim 1?
No. Sodium chloride appears only in dependent claims 2 and 3.
-
Are only 20 mL, 50 mL, and 100 mL volumes protected?
Those volumes are protected under claim 4. Other volumes may still be covered under claim 1 if claim 1’s other elements are met.
-
What single change is most likely to defeat claim 1 without changing the drug?
Changing the product so it is not disposed within a sealed glass container, since that is a required element of claim 1.
-
If a competitor matches the concentration but not the excipient range, is it still at risk?
Yes. If the product still meets claim 1 elements, it can be covered even if it avoids claim 2 or 3 by changing NaCl.
References
[1] United States Patent 8,242,158. (Claims provided in user prompt).
